Abstract
This chapter describes a system using adeno-associated viral (AAV) vector to deliver hypoxia-inducible gene expression to ischemic hearts. The hypoxia induction of gene expression in this system is based on the accumulation of hypoxia-inducible factor-1 (HIF-1) in ischemic hearts and the use of hypoxia-response element (HRE) identified from the enhancers of genes, the expression of which can be induced by hypoxia. The methods of plasmid and AAV vector construction for hypoxia-inducible gene expression, viral vector production and purification, and viral titer determination are described. This chapter also illustrates the methods that can be used to test hypoxia-inducible gene expression in vitro and in vivo, including hypoxia treatment of cultured cells, generation of murine ischemic heart models, and analysis of gene expression.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jones, S. P., Greer, J. J., Kakkar, A. K., et al. (2004) Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 286, H276–H282.
Jones, S. P., Greer, J. J., van Haperen, R., Duncker, D. J., de Crom, R., and Lefer, D. J. (2003) Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc. Natl. Acad. Sci. USA 100, 4891–4896.
Woo, Y. J., Zhang, J. C., Vijayasarathy, C., et al. (1998) Recombinant adenovirus-mediated cardiac gene transfer of Superoxide dismutase and catalase attenuates postischemic contractile dysfunction. Circulation 98, II255–II260; discussion II260–II261.
Mack, C. A., Patel, S. R., Schwarz, E. A., et al. (1998) Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J. Thorac. Cardiovasc. Surg. 115, 168–176; discussion 176–177.
Giordano, F. J., Ping, P., McKirnan, M. D., et al. (1996) Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart [see comments]. Nat. Med. 2, 534–539.
Laham, R. J., Simons, M., and Sellke, F. (2001) Gene transfer for angiogenesis in coronary artery disease. Annu. Rev. Med. 52, 485–502.
Banai, S., Jaklitsch, M. T., Shou, M., et al. (1994) Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89, 2183–2189.
Lee, R. J., Springer, M. L., Blanco-Bose, W. E., Shaw, R., Ursell, P. C., and Blau, H. M. (2000) VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 102, 898–901.
Springer, M. L., Chen, A. S., Kraft, P. E., Bednarski, M., and Blau, H. M. (1998) VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol. Cell 2, 549–558.
Dennery, P. A., Sridhar, K. J., Lee, C. S., et al. (1997) Heme oxygenase-mediated resistance to oxygen toxicity in hamster fibroblasts. J. Biol. Chem. 272, 14937–14942.
Suttner, D. M. and Dennery, P. A. (1999) Reversal of HO-1 related cytoprotection with increased expression is due to reactive iron. FASEB J. 13, 1800–1809.
Bohl, D., Salvetti, A., Moullier, P., and Heard, J. M. (1998) Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 92, 1512–1517.
Hofmann, A., Nolan, G. P., and Blau, H. M. (1996) Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette [see comments]. Proc. Natl. Acad. Sci. USA 93, 5185–5190.
Bohl, D., Naffakh, N., and Heard, J. M. (1997) Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts [see comments]. Nat. Med. 3, 299–305.
Gossen, M. and Bujard, H. (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. USA 89, 5547–5551.
Wang, Y., O’Malley, B. W., Jr., Tsai, S. Y., and O’Malley, B. W. (1994) A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. USA 91, 8180–8184.
Blau, H. M. and Rossi, F. M. (1999) Tet B or not tet B: advances in tetracycline-inducible gene expression [comment]. Proc. Natl. Acad. Sci. USA 96, 797–799.
Rossi, F. M., Guicherit, O. M., Spicher, A., et al. (1998) Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by pl6. Nat. Genet. 20, 389–393.
Kringstein, A. M., Rossi, F. M., Hofmann, A., and Blau, H. M. (1998) Graded transcriptional response to different concentrations of a single transactivator. Proc. Natl. Acad. Sci. USA 95, 13670–13675.
Wang, G. L., Jiang, B. H., Rue, E. A., and Semenza, G. L. (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92, 5510–5514.
Wang, G. L. and Semenza, G. L. (1995) Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270, 1230–1237.
Jiang, B. H., Rue, E., Wang, G. L., Roe, R., and Semenza, G. L. (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271, 17771–17778.
Su, H., Arakawa-Hoyt, J., and Kan, Y. W. (2002) Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc. Natl. Acad. Sci. USA 99, 9480–9485.
Pachori, A. S., Melo, L. G., Hart, M. L., et al. (2004) Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. Proc. Natl. Acad. Sci. USA 101, 12282–12287.
Su, H., Lu, R., and Kan, Y. W. (2000) Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc. Natl. Acad. Sci. USA 97, 13801–13806.
Du, L., Kido, M., Lee, D. V., et al. (2004) Differential myocardial gene delivery by recombinant serotype-specific adeno-associated viral vectors. Mol Ther. 10, 604–608.
Semenza, G. L. and Wang, G. L. (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol. 12, 5447–5454.
Wang, G. L. and Semenza, G. L. (1993) General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. USA 90, 4304–4308.
Chavez, J. C., Agani, F., Pichiule, P., and LaManna, J. C. (2000) Expression of hypoxia-inducible factor-1 alpha in the brain of rats during chronic hypoxia. J. Appl Physiol. 89, 1937–1942.
Ruan, H., Su, H., Hu, L., Lamborn, K. R., Kan, Y. W., and Deen, D. F. (2001) A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 3, 255–263.
Shibata, T., Giaccia, A. J., and Brown, J. M. (2000) Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther. 7, 493–498.
Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., and Wilson, J. M. (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl Acad. Sci. USA 99, 11854–11859.
Rutledge, E. A., Halbert, C. L., and Russell, D. W. (1998) Infectious clones and vectors derived from adeno-assoicated virus (AAV) serotypes other than AAV type 2. J. Virol 72, 309–319.
Muramatsu, S., Mizukami, H., Young, N. S., and Brown, K. E. (1996) Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology 221, 208–217.
Chiorini, J. A., Yang, L., Liu, Y., Safer, B., and Kotin, R. M. (1997) Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol 71, 6823–6833.
Chiorini, J. A., Kim, F., Yang, L., and Kotin, R. M. (1999) Cloning and characterization of adeno-associated virus type 5. J. Virol 73, 1309–1319.
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., and Wilson, J. M. (1999) Gene therapy vectors based on adeno-associated virus type 1. J. Virol 73, 3994–4003.
Du, L., Sullivan, C. C., Chu, D., et al. (2003) Signaling molecules in nonfamilial pulmonary hypertension. N. Engl. J. Med. 348, 500–509.
Clark, K. R., Liu, X., McGrath, J. P., and Johnson, P. R. (1999) Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum. Gene Ther. 10, 1031–1039.
Zolotukhin, S., Potter, M., Zolotukhin, L, et al. (2002) Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28, 158–167.
Zolotukhin, S., Byrne, B. J., Mason, E., et al. (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973–985.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc.
About this protocol
Cite this protocol
Su, H., Kan, Y.W. (2007). Adeno-Associated Viral Vector-Delivered Hypoxia-Inducible Gene Expression in Ischemic Hearts. In: Zhang, J., Rokosh, G. (eds) Cardiac Gene Expression. Methods in Molecular Biology, vol 366. Humana Press. https://doi.org/10.1007/978-1-59745-030-0_19
Download citation
DOI: https://doi.org/10.1007/978-1-59745-030-0_19
Publisher Name: Humana Press
Print ISBN: 978-1-58829-352-7
Online ISBN: 978-1-59745-030-0
eBook Packages: Springer Protocols